文献速递乳腺癌

激素敏感型人表皮生长因子受体2阴性晚期乳腺癌内分泌与靶向治疗的序贯策略

Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-07-05

本文以病例讨论形式梳理激素敏感型人表皮生长因子受体2(HER2)阴性晚期乳腺癌内分泌与靶向治疗的序贯策略,结合MAINTAIN临床试验结果讨论CDK4/6抑制剂进展后继续该类药物并更换内分泌搭档的可能性,并汇总针对PIK3CA、ESR1、AKT1和PTEN可靶向alterations的近期临床试验结果。

要点

  • 激素敏感型HER2阴性晚期乳腺癌的内分泌与靶向治疗选择与序贯正在快速演变。
  • MAINTAIN试验开始回答CDK4/6抑制剂进展后能否继续该类药物并更换内分泌搭档的问题。
  • 作者临床策略优先识别有CDK4/6抑制剂后临床试验高质量疗效证据的可靶向突变,并平衡合并症与患者意愿。

核心结论

  • 近期多项临床试验将新兴靶向治疗与PIK3CA、ESR1、AKT1和PTEN的可靶向改变联系起来,呈现有临床意义的结果。
  • 该领域持续的药物开发推迟了患者接受化疗的时间,并有望帮助这些以口服治疗为主的患者维持较高的生活质量。

研究设计与样本

  • 肿瘤学大查房系列文章,先呈现病例,再描述诊断与管理挑战、复习相关文献,并总结作者建议的管理方法。
  • 本文呈现一例激素敏感型HER2低表达转移性乳腺癌患者,在一线CDK4/6抑制剂联合芳香化酶抑制剂进展后接受循环肿瘤DNA下一代测序以更好地指导治疗选择。

主要发现

  • MAINTAIN临床试验近期发表的结果开始回答该患者群体中的一个重要问题,即一线CDK4/6抑制剂已确立的获益能否通过进展后继续该药物类别并选择替代内分泌治疗搭档而进一步延伸。
  • 本文讨论的近期多项临床试验将新兴靶向治疗与PIK3CA、ESR1、AKT1和PTEN的可靶向改变联系起来,呈现有临床意义的结果。

临床怎么用

  • 作者临床策略在该患者群体中优先识别有CDK4/6抑制剂后临床试验高质量疗效证据的可靶向突变,同时平衡合并症与患者优先的照护需求。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Optimizing the selection and sequencing of endocrine and targeted therapies for hormone-sensitive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer is a rapidly evolving field owing in large part to an increasing pace of drug development coupled with a greater understanding of the genomic drivers of breast cancer. The recently published results from the MAINTAIN clinical trial begin to answer an important question in this patient population-can the well-established benefit with first-line cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors be stretched further by continuing this drug class beyond progression and selecting an alternate endocrine therapy partner? We present a case of a patient with hormone-sensitive HER2 low metastatic breast cancer who underwent circulating tumor DNA next-generation sequencing to better inform her treatment options after progression on first-line therapy with a CDK 4/6 inhibitor and aromatase inhibitor. Our clinical approach in this patient population prioritizes the identification of actionable mutations with high-quality evidence for efficacy on the basis of clinical trials post-CDK 4/6 inhibitors, while balancing comorbidities and patient priorities for care. Several recent clinical trials discussed herein present clinically meaningful results linking emerging targeted therapies to actionable alterations in PIK3CA, ESR1, AKT1, and PTEN. Continued drug development in this space delays time to treatment with chemotherapy, and hopefully contributes to maintaining a high quality of life for these patients on primarily oral-based therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jackson EB, Chia SKL. Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2023. PMID: 37406271. doi:10.1200/JCO.23.00759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。